Skip to content

Adjuvant Benefit of NMES to Supervised Exercise in Patients With IC

Adjuvant Benefit of Neuromuscular Electrical Stimulation to Supervised Exercise in Patients With Intermittent Claudication

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02429310
Acronym
AdjIC
Enrollment
42
Registered
2015-04-29
Start date
2014-12-31
Completion date
2016-10-31
Last updated
2020-10-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intermittent Claudication, Lower Limb Arterial Disease, Peripheral Vascular Disease

Keywords

Intermittent Claudication, IC, Peripheral Arterial Disease, Peripheral Vascular Disease, Peripheral Arterial Occlusive Disease, Lower Limb Arterial Disease, Supervised Exercise Therapy, Supervised Exercise Programme, Exercise Therapy

Brief summary

This study will assess the adjuvant benefit of a neuromuscular electrical stimulation device to standard treatment of supervised exercise in patients suffering from symptoms and effects of lower limb Intermittent Claudication.

Detailed description

The circulation of blood around the body is dependent on effective pumping of the heart. Patients with claudication experience pain or discomfort in their legs usually during activity such as walking, which goes away at rest. Claudication is a symptom of peripheral arterial disease (PAD). If left untreated, patients can develop arterial insufficiency which can lead to various complications such as swelling, painful legs, reduced healing of injuries and the loss of limbs in extreme conditions. PAD can be defined as a narrowing of the arteries reducing blood flow. It is most commonly due to atherosclerosis, and has associations with heart disease, stroke, and diabetes. Its incidence is estimated at 7-14% in the general population, increasing with age to about 20% in the over-seventies. It is associated with effects on mobility, skin condition and quality of life. Symptoms include pain in the legs on walking (intermittent claudication), pain at rest (particularly at night), gangrene, and limb loss. Management of PAD is based on encouraging exercise, and modification of risk factors such as smoking, high blood pressure, high cholesterol and diabetes. In patients with PAD, exercise tolerance is often limited. Severe symptoms and disease can be treated by procedures such as balloon angioplasty, stenting or surgical bypass, but these procedures have risks. There also remains a percentage of patients who are not suitable for revascularisation, and have few options besides amputation available to them. Current NICE guidelines (NICE Clinical Guideline 147: Lower Limb Peripheral Arterial Disease:Diagnosis and Management guidance.nice.org.uk/cg147) advise a supervised exercise programme should be offered to all patients with IC as well as best medical therapy. Regular exercise has shown to significantly improve symptoms of IC in patients, but the effects of this benefit quickly revert upon inactivity. Some trials have shown that increasing the blood flow in the legs over time using medical devices (intermittent pneumatic compression, muscle stimulators), in addition to maximal medical and surgical therapy, can increase claudication distance, absolute walking distance, decrease rest pain, and reduce amputation rates. In our unit it has become apparent that there are an increasing number of medical devices available for circulatory support, either for use as an inpatient, out-patient, or a member of the general public. The supporting evidence for these is variable in scientific and clinical content or relevance, and requires clinical trials to evaluate further. The device being used in this study activates the pumping action of the leg muscles by providing neuromuscular electrical stimulation (NMES) to cause foot muscle contraction and relaxation. This squeezes blood back towards the heart, improving circulation. The investigators wish to evaluate whether NMES using this device has the same beneficial effects in patients with claudication when used in conjunction with supervised exercise.

Interventions

This is a neuromuscular electrical stimulation device

Sponsors

Imperial College London
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients with intermittent claudication who have the following are eligible for the study: * All ethnic groups, male or female above the age of 18 years. * Diagnosis of intermittent claudication * Be of non-childbearing potential; OR using adequate contraception and have a negative urine pregnancy test result within 24 hours, if appropriate, before using the study device. * Blood pressure currently under moderate control (\< 160/100mmHg) * No current foot ulceration

Exclusion criteria

* Patients meeting any of the following criteria are to be excluded: * Has an unstable condition (eg, psychiatric disorder, a recent history of substance abuse) or otherwise thought to be unreliable or incapable of complying with the study protocol. * Has renal failure * Has diabetes * Has an ankle-brachial pressure index (ABPI) \>0.9 * Has any metal implants * Pregnant * Has a cardiac pacemaker or defibrillator device * Has recent lower limb injury or lower back pain * Has current foot ulceration or other skin ulcers * Has foot deformities * Has any disorder that, in the opinion of the Investigator, might interfere with the conduct of the study.

Design outcomes

Primary

MeasureTime frameDescription
Initial Walking Distance Measured by TreadmillChange in baseline treadmill walking distance at 6 weeks (positive numbers indicate increase from baseline, negative numbers indicate decrease from baseline) - 6 week - baseline values.For the initial claudication distance measurement, a fixed load treadmill test will be carried out at 3.5 km/h with a 10% gradient. The initial claudication distance (ICD) is the distance walked until the onset of pain.
Absolute Walking Distance Measured by TreadmillChange in baseline treadmill walking distance at 6 weeks (positive numbers indicate increase from baseline, negative numbers indicate decrease from baseline)For the absolute claudication distance measurement, a fixed load treadmill test will be carried out at 3.5 km/h with a 10% gradient. The absolute claudication distance (ACD) is the distance walked before the participant is forced to stop due to typical pain.

Secondary

MeasureTime frameDescription
Symptomatic Scores by QuestionnaireChange in baseline questionnaire scores at 6 weeksValidated questionnaires including the Edinburgh Claudication Questionnaire and Intermittent Claudication Questionnaire will be obtained at baseline and week 6.
Quality of Life Scores Measured by QuestionnaireChange in baseline quality of life at 6 weeksValidated questionnaires including the Euro-Quol 5D and Short Form 36 will be measured at baseline and 6 weeks.
Femoral Haemodynamics Measured by Femoral Artery Duplex UltrasonographyChange in baseline femoral haemodynamics at 6 weeks - 6 weeks - baseline.Ultrasound assessment of blood flow dynamics in the femoral artery will be obtained at rest, and if randomised to the intervention group, whilst using the device.
Serum Metabolic ProfileChange of profile at baseline and 6 weeksA serum sample will be collected at baseline and at 6 weeks. Mass spectroscopy and nuclear magnetic resonance spectroscopy analysis will be carried out.
Urine Metabolic ProfileChange of profile at baseline and at 6 weeksA urine sample will be collected at baseline and at 6 weeks. Mass spectroscopy and nuclear magnetic resonance spectroscopy analysis will be carried out.
Laser Doppler Flow Measured by Optical LaserChange in baseline flowmetry at 6 weeksOptical laser flowmetry probes will be used to assess the superficial skin circulation and temperature.

Countries

United Kingdom

Participant flow

Participants by arm

ArmCount
Supervised Exercise Only
This is the cohort of patients with Intermittent Claudication that will receive standard care of a supervised exercise programme only.
22
NMES + Supervised Exercise
This cohort of patients with Intermittent Claudication will receive the standard care of supervised exercise plus the use of a Revitive IX neuromuscular electrical stimulation device (Intervention) as per the protocol. The adjunctive benefit of the latter intervention compared to standard treatment alone will then be assessed. Revitive IX: This is a neuromuscular electrical stimulation device
20
Total42

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyLost to Follow-up12
Overall StudyProtocol Violation11

Baseline characteristics

CharacteristicNMES + Supervised ExerciseTotalSupervised Exercise Only
Age, Continuous66 years
STANDARD_DEVIATION 8
67 years
STANDARD_DEVIATION 9
68 years
STANDARD_DEVIATION 11
Race and Ethnicity Not Collected0 Participants
Region of Enrollment
United Kingdom
20 participants40 participants22 participants
Sex: Female, Male
Female
5 Participants11 Participants6 Participants
Sex: Female, Male
Male
15 Participants31 Participants16 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 200 / 17
other
Total, other adverse events
0 / 200 / 17
serious
Total, serious adverse events
0 / 200 / 17

Outcome results

Primary

Absolute Walking Distance Measured by Treadmill

For the absolute claudication distance measurement, a fixed load treadmill test will be carried out at 3.5 km/h with a 10% gradient. The absolute claudication distance (ACD) is the distance walked before the participant is forced to stop due to typical pain.

Time frame: Change in baseline treadmill walking distance at 6 weeks (positive numbers indicate increase from baseline, negative numbers indicate decrease from baseline)

ArmMeasureValue (MEDIAN)
Supervised Exercise OnlyAbsolute Walking Distance Measured by Treadmill146.7 metres
NMES + Supervised ExerciseAbsolute Walking Distance Measured by Treadmill167.4 metres
Primary

Initial Walking Distance Measured by Treadmill

For the initial claudication distance measurement, a fixed load treadmill test will be carried out at 3.5 km/h with a 10% gradient. The initial claudication distance (ICD) is the distance walked until the onset of pain.

Time frame: Change in baseline treadmill walking distance at 6 weeks (positive numbers indicate increase from baseline, negative numbers indicate decrease from baseline) - 6 week - baseline values.

ArmMeasureValue (MEDIAN)
Supervised Exercise OnlyInitial Walking Distance Measured by Treadmill65.60 metres
NMES + Supervised ExerciseInitial Walking Distance Measured by Treadmill95.50 metres
Secondary

Femoral Haemodynamics Measured by Femoral Artery Duplex Ultrasonography

Ultrasound assessment of blood flow dynamics in the femoral artery will be obtained at rest, and if randomised to the intervention group, whilst using the device.

Time frame: Change in baseline femoral haemodynamics at 6 weeks - 6 weeks - baseline.

Secondary

Laser Doppler Flow Measured by Optical Laser

Optical laser flowmetry probes will be used to assess the superficial skin circulation and temperature.

Time frame: Change in baseline flowmetry at 6 weeks

Secondary

Quality of Life Scores Measured by Questionnaire

Validated questionnaires including the Euro-Quol 5D and Short Form 36 will be measured at baseline and 6 weeks.

Time frame: Change in baseline quality of life at 6 weeks

Secondary

Serum Metabolic Profile

A serum sample will be collected at baseline and at 6 weeks. Mass spectroscopy and nuclear magnetic resonance spectroscopy analysis will be carried out.

Time frame: Change of profile at baseline and 6 weeks

Secondary

Symptomatic Scores by Questionnaire

Validated questionnaires including the Edinburgh Claudication Questionnaire and Intermittent Claudication Questionnaire will be obtained at baseline and week 6.

Time frame: Change in baseline questionnaire scores at 6 weeks

Secondary

Urine Metabolic Profile

A urine sample will be collected at baseline and at 6 weeks. Mass spectroscopy and nuclear magnetic resonance spectroscopy analysis will be carried out.

Time frame: Change of profile at baseline and at 6 weeks

Source: ClinicalTrials.gov · Data processed: Feb 19, 2026